Healthcare -
Biotechnology - NASDAQ - US
$ 3.345
1.36 %
$ 634 M
Market Cap
-7.78
P/E
1. INTRINSIC VALUE
Balance Sheet
Arbutus Biopharma Corporation
| Current Assets | 132 M |
| Cash & Short-Term Investments | 126 M |
| Receivables | 1.78 M |
| Other Current Assets | 4.25 M |
| Non-Current Assets | 12.4 M |
| Long-Term Investments | 6.28 M |
| PP&E | 6.09 M |
| Other Non-Current Assets | 0 |
| Current Liabilities | 22.5 M |
| Accounts Payable | 3.22 M |
| Short-Term Debt | 425 K |
| Other Current Liabilities | 18.8 M |
| Non-Current Liabilities | 15.9 M |
| Long-Term Debt | 8.3 M |
| Other Non-Current Liabilities | 7.6 M |
EFFICIENCY
Earnings Waterfall
Arbutus Biopharma Corporation
| Revenue | 18.1 M |
| Cost Of Revenue | 73.7 M |
| Gross Profit | -55.6 M |
| Operating Expenses | 96.2 M |
| Operating Income | -78.1 M |
| Other Expenses | -5.25 M |
| Net Income | -72.8 M |
RATIOS
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis
Arbutus Biopharma Corporation
| Net Income | -72.8 M |
| Depreciation & Amortization | 1.4 M |
| Capital Expenditures | -1.01 M |
| Stock-Based Compensation | 9.3 M |
| Change in Working Capital | -18.2 M |
| Others | -23.8 M |
| Free Cash Flow | -86.9 M |
Wall Street Analysts Price Targets
Arbutus Biopharma Corporation
ABUS has no price targets from Wall Street.
4. DIVIDEND
ANALYSIS
ABUS does not distribute dividends.
5. COMPETITION
6. Ownership
Insider Ownership
Arbutus Biopharma Corporation
Sold
0-3 MONTHS
0 USD 0
3-6 MONTHS
32.6 K USD 1
6-9 MONTHS
0 USD 0
9-12 MONTHS
78.8 K USD 4
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
| Date | Value | Insider | Amount | Avg Price |
|---|---|---|---|---|
|
5 months ago
Aug 14, 2024
|
Sell 32.6 K
USD
|
MANCHESTER KEITH S
Director
|
- 8846
|
3.6895 USD |
|
11 months ago
Feb 02, 2024
|
Sell 10.1 K
USD
|
Sims Karen
Chief Medical Officer
|
- 4358
|
2.3125 USD |
|
11 months ago
Feb 02, 2024
|
Sell 22.2 K
USD
|
HASTINGS DAVID C
Chief Financial Officer
|
- 9593
|
2.3125 USD |
|
11 months ago
Feb 02, 2024
|
Sell 23.1 K
USD
|
Sofia Michael J.
Chief Scientific Officer
|
- 9982
|
2.3125 USD |
|
11 months ago
Feb 02, 2024
|
Sell 23.5 K
USD
|
McElhaugh Michael J.
Interim President & CEO
|
- 10164
|
2.3125 USD |
|
3 years ago
Dec 01, 2021
|
Sell 1.02 M
USD
|
Sofia Michael J.
Chief Scientific Officer
|
- 200000
|
5.09 USD |
|
3 years ago
Feb 09, 2021
|
Sell 100 K
USD
|
McElhaugh Michael J.
Chief Business Officer
|
- 20000
|
5 USD |
|
4 years ago
Dec 14, 2020
|
Sell 150 K
USD
|
McElhaugh Michael J.
Chief Business Officer
|
- 30000
|
5 USD |
|
4 years ago
Dec 14, 2020
|
Sell 50 K
USD
|
McElhaugh Michael J.
Chief Business Officer
|
- 10000
|
5.0032 USD |
|
4 years ago
Jul 23, 2020
|
Sell 100 K
USD
|
McElhaugh Michael J.
Chief Business Officer
|
- 20000
|
5.01 USD |
|
6 years ago
Aug 13, 2018
|
Sell 40.4 K
USD
|
Sofia Michael J.
Chief Scientific Officer
|
- 4250
|
9.5143 USD |
|
6 years ago
Aug 13, 2018
|
Sell 40.4 K
USD
|
Sofia Michael J.
Chief Scientific Officer
|
- 4250
|
9.5143 USD |
|
6 years ago
Jul 11, 2018
|
Sell 100 K
USD
|
Sofia Michael J.
Chief Scientific Officer
|
- 10000
|
10 USD |
|
6 years ago
Jul 06, 2018
|
Sell 84.5 K
USD
|
Sofia Michael J.
Chief Scientific Officer
|
- 10000
|
8.45 USD |
|
6 years ago
Jul 09, 2018
|
Sell 89.1 K
USD
|
Sofia Michael J.
Chief Scientific Officer
|
- 10000
|
8.906 USD |
|
6 years ago
Jul 03, 2018
|
Sell 80 K
USD
|
Sofia Michael J.
Chief Scientific Officer
|
- 10000
|
8 USD |
|
6 years ago
Jul 05, 2018
|
Sell 84 K
USD
|
Sofia Michael J.
Chief Scientific Officer
|
- 10000
|
8.4 USD |
|
7 years ago
Jan 12, 2018
|
Bought
4.73 M USD
|
SVF Investments (UK) Ltd
10 percent owner
|
+ 664000
|
7.13 USD |
|
7 years ago
Jan 12, 2018
|
Bought
4.73 M USD
|
Dexxon Holdings Ltd.
10 percent owner
|
+ 664000
|
7.13 USD |
|
7 years ago
Jan 12, 2018
|
Bought
4.73 M USD
|
QVT Associates GP LLC
director, 10 percent owner:
|
+ 664000
|
7.13 USD |
|
7 years ago
Jan 12, 2018
|
Bought
4.73 M USD
|
VIKING GLOBAL INVESTORS LP
10 percent owner
|
+ 664000
|
7.13 USD |
|
7 years ago
Jan 12, 2018
|
Bought
4.73 M USD
|
VIKING GLOBAL PERFORMANCE LLC
10 percent owner
|
+ 664000
|
7.13 USD |
|
7 years ago
Jan 12, 2018
|
Bought
4.73 M USD
|
Lo Andrew
10 percent owner
|
+ 664000
|
7.13 USD |
|
7 years ago
Jan 12, 2018
|
Bought
4.73 M USD
|
Roivant Sciences Ltd.
10 percent owner
|
+ 664000
|
7.13 USD |
|
7 years ago
Jan 12, 2018
|
Bought
4.73 M USD
|
Machado Patrick
10 percent owner
|
+ 664000
|
7.13 USD |
|
7 years ago
Oct 16, 2017
|
Bought
3.56 M USD
|
Dexxon Holdings Ltd.
10 percent owner
|
+ 500000
|
7.13 USD |
|
7 years ago
Oct 16, 2017
|
Bought
3.56 M USD
|
QVT Associates GP LLC
director, 10 percent owner:
|
+ 500000
|
7.13 USD |
|
7 years ago
Oct 16, 2017
|
Bought
3.56 M USD
|
SVF Investments (UK) Ltd
10 percent owner
|
+ 500000
|
7.13 USD |
|
7 years ago
Oct 16, 2017
|
Bought
3.56 M USD
|
VIKING GLOBAL INVESTORS LP
10 percent owner
|
+ 500000
|
7.13 USD |
|
7 years ago
Oct 16, 2017
|
Bought
3.56 M USD
|
VIKING GLOBAL PERFORMANCE LLC
10 percent owner
|
+ 500000
|
7.13 USD |
|
7 years ago
Oct 16, 2017
|
Bought
3.56 M USD
|
Lo Andrew
10 percent owner
|
+ 500000
|
7.13 USD |
|
7 years ago
Oct 16, 2017
|
Bought
3.56 M USD
|
Roivant Sciences Ltd.
10 percent owner
|
+ 500000
|
7.13 USD |
|
7 years ago
Oct 16, 2017
|
Bought
3.56 M USD
|
Machado Patrick
10 percent owner
|
+ 500000
|
7.13 USD |
|
7 years ago
Oct 03, 2017
|
Sell 80 K
USD
|
Sofia Michael J.
Chief Scientific Officer
|
- 10000
|
8 USD |
|
7 years ago
Aug 15, 2017
|
Sell 37.5 K
USD
|
Sofia Michael J.
Chief Scientific Officer
|
- 10000
|
3.75 USD |
|
7 years ago
Aug 15, 2017
|
Sell 73.5 K
USD
|
Sofia Michael J.
Chief Scientific Officer
|
- 20000
|
3.675 USD |
|
9 years ago
Aug 24, 2015
|
Bought
6.95 K USD
|
HENRIQUES RICHARD C JR
Director
|
+ 1000
|
6.95 USD |
7. News
Arbutus Provides 2025 Corporate and Financial Update
Initiating Phase 2b clinical trial in first half of 2025 after achieving a meaningful functional cure rate in cHBV patients treated with imdusiran and interferon
globenewswire.com
- 2 weeks ago
Arbutus: Positive Imdusiran Data Leads To Phase 2B Development
Company's phase 2a trial of Imdusiran with pegylated interferon alfa-2a achieved a functional cure in 25% of Hepatitis B patients. The company is developing its own in-house oral PD-L1 inhibitor, AB-101, with preliminary data expected in the first half of 2025. The global Hepatitis B Virus market size is anticipated to reach $6.65 billion by 2034.
seekingalpha.com
- 3 weeks ago
Arbutus to Participate in H.C Wainwright @ Home Virtual Fireside Chat
WARMINSTER, Pa., Nov. 26, 2024 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), (“Arbutus” or the “Company”), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop a functional cure for people with chronic hepatitis B virus (cHBV) infection, today announced that the Company will participate in the virtual H.C Wainwright @ Home fireside chat series taking place on Tuesday, December 3, 2024 at 11:00 am ET.
globenewswire.com
- 2 months ago
Arbutus' Imdusiran Achieves Functional Cure in cHBV Patients when Combined with a Short Course of Interferon
50% of patients who had baseline HBsAg levels less than 1000 IU/mL achieved functional cure in Cohort A1 of the IM-PROVE I Phase 2a clinical trial
globenewswire.com
- 2 months ago
Arbutus and Barinthus Bio Announce New Data from the IM-PROVE II Trial Showing that the Addition of Nivolumab Increased Rates of HBsAg Loss in People with Chronic Hepatitis B
Significantly greater mean declines in HBsAg levels (p
globenewswire.com
- 2 months ago
Arbutus to Present at Jefferies London Healthcare Conference
WARMINSTER, Pa., Nov. 14, 2024 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), (“Arbutus” or the “Company”), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop a functional cure for people with chronic hepatitis B virus (cHBV) infection, today announced that the Company will present at and host one-on-one meetings at the following upcoming investor conference:
globenewswire.com
- 2 months ago
Arbutus Biopharma Corporation (ABUS) Q3 2024 Earnings Call Transcript
Arbutus Biopharma Corporation (NASDAQ:ABUS ) Q3 2024 Results Conference Call November 6, 2024 8:45 AM ET Company Participants Lisa Caperelli - VP, Investor Relations Mike McElhaugh - Interim President, CEO & Director Karen Sims - Chief Medical Officer Dave Hastings - CFO Conference Call Participants Anthea Li - Jefferies Roy Buchanan - Citizens JMP Keay Nakae - Chardan Brian Skorney - Baird Operator Good day, and thank you for standing by. Welcome to the Arbutus Biopharma 2024 Third Quarter Financial Results and Corporate Update.
seekingalpha.com
- 2 months ago
Arbutus Biopharma (ABUS) Reports Q3 Loss, Lags Revenue Estimates
Arbutus Biopharma (ABUS) came out with a quarterly loss of $0.10 per share in line with the Zacks Consensus Estimate. This compares to loss of $0.12 per share a year ago.
zacks.com
- 2 months ago
Arbutus to Report Third Quarter 2024 Financial Results and Provide Corporate Update
WARMINSTER, Pa., Oct. 23, 2024 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), (“Arbutus” or the “Company”) a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop a functional cure for people with chronic hepatitis B virus (cHBV) infection, today announced that it has scheduled its third quarter 2024 financial results and corporate update for Wednesday, November 6, 2024. The schedule for the press release and conference call/webcast are as follows:
globenewswire.com
- 3 months ago
Arbutus Announces Multiple Abstracts Highlighting Imdusiran Data Accepted for Presentation at AASLD - The Liver Meeting® 2024
WARMINSTER, Pa., Oct. 15, 2024 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), (“Arbutus” or the “Company”) a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop a functional cure for people with chronic hepatitis B virus (cHBV) infection, today announced that clinical data with imdusiran, an RNAi therapeutic, will be highlighted in four poster presentations at the American Association for the Study of Liver Diseases (AASLD) – The Liver Meeting ® 2024, scheduled from November 15-19, 2024 in San Diego, CA. This includes two late-breaking posters with imdusiran data from the IM-PROVE I and IM-PROVE II Phase 2a clinical trials.
globenewswire.com
- 3 months ago
Has Arbutus Biopharma (ABUS) Outpaced Other Medical Stocks This Year?
Here is how Arbutus Biopharma (ABUS) and Astrazeneca (AZN) have performed compared to their sector so far this year.
zacks.com
- 4 months ago
Arbutus to Participate in Two Upcoming Investor Conferences
WARMINSTER, Pa., Sept. 03, 2024 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS) (“Arbutus” or the “Company”), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop a functional cure for people with chronic hepatitis B virus (cHBV) infection, today announced that the Arbutus management team will participate in and host one-on-one meetings at the following two upcoming investor conferences which are being held in New York:
globenewswire.com
- 4 months ago
8. Profile
Summary
Arbutus Biopharma Corporation ABUS
COUNTRY
US
INDUSTRY
Biotechnology
MARKET CAP
$ 634 M
Dividend Yield
0.00%
Description
Arbutus Biopharma Corporation, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection, SARS-CoV-2, and other coronaviruses in the United States. Its HBV product pipeline consists of AB-729, a proprietary subcutaneously delivered RNA interference product candidate, which in Phase Ia/Ib clinical trial targeted to hepatocytes that inhibits viral replication and reduces various HBV antigens using novel covalently conjugated N-acetylgalactosamine (GalNAc) delivery technology; and AB-836, an oral capsid inhibitor that suppresses HBV DNA replication. The company's research and development programs include AB-161, an oral HBV RNA destabilizer to destabilize HBV RNA, which leads in the reduction of HBsAg and other viral proteins; AB-101, an oral PD-L1 inhibitor to reawaken patients' HBV-specific immune response; and small molecule antiviral medicines to treat coronaviruses, including COVID-19. It has strategic alliance, licensing, and research collaboration agreements with Talon Therapeutics, Inc.; Gritstone Oncology, Inc.; Alnylam Pharmaceuticals, Inc.; Qilu Pharmaceuticals Co, Ltd.; Assembly Biosciences, Inc.; Acuitas Therapeutics, Inc.; and Antios Therapeutics, Inc. Arbutus Biopharma Corporation also has a clinical collaboration agreement with Vaccitech plc to evaluate a triple combination of AB-729 for the treatment of chronic HBV infection. The company was formerly known as Tekmira Pharmaceuticals Corporation and changed its name to Arbutus Biopharma Corporation in July 2015. Arbutus Biopharma Corporation is headquartered in Warminster, Pennsylvania.
Contact
701 Veterans Circle, Warminster, PA, 18974
https://www.arbutusbio.com
IPO
Date
July 26, 2007
Employees
73
Officers
Dr. Karen Sims M.D., Ph.D.
Chief Medical Officer
Ms. Lisa M. Caperelli
Vice President of Investor Relations
Ms. Shannon Briscoe SPHR
Vice President of Human Resources
Mr. Michael J. McElhaugh
Co-Founder, Interim President, Chief Executive Officer & Director
Mr. David C. Hastings CPA
Chief Financial Officer & Chief Accounting Officer
Mr. J. Christopher Naftzger BA, Esq., J.D.
General Counsel, Chief Compliance Officer & Secretary
Mr. R. Hector Mackay-Dunn B.A., J.D., L.L.B., Q.C.
Corporate Secretary